Advertisement

Topics

Search Results for "Mirrx Therapeutics"

20:33 EDT 30th March 2017 | BioPortfolio

Matching Channels

Tuberculosis Vaccines and Therapeutics

The WHO estimates that the largest number of new tuberculosis (TB) cases in 2008 occurred in the South-East Asia Region, which accounted for 34% of incident cases globally. However, the estimated inci...

KIACTA

KIACTA™ (also known as eprodisate) is an orally bioavailable small molecule intended for the treatment of AA amyloidosis, an orphan indication that results from long-standing inflammatory cond...

Anthrax Vaccines and Therapeutics

Anthrax is a zoonotic disease caused by the spore-forming bacterium Bacillus anthracis. The disease most commonly occurs in mammals (e.g., cattle, sheep, goats, camels, antelope. Anthrax occurs in hu...

AUT00063

AUT00063 develpoed by Autifony Therapeutics, is a novel, orally active small molecule designed to selectively modulate Kv3 potassium channels, which are important in central auditory processing. Pre...

Facebook - BioPortfolio Pages

BioPortfolio has launched a number of Facebook pages to allow our visitors to keep track with latest news, published paper and clinical trials by lead biotechnology and healthcare topics:- &nbs...

Matching News

Research Reports Initiation on Biotech Stocks -- Regulus Therapeutics, Abeona Therapeutics, ...

Regulus Therapeutics  San Diego, Californiaheadquartered Regulus Therapeutics Inc.'s stock finished Thursday's session 2.08% lower at $2.35with a total trading volume of 187,480 Read more...

Research Reports Coverage on Biotech Stocks -- Celldex Therapeutics, Amicus Therapeutics, ...

http://stock-callers.com/registration Celldex Therapeutics  On Thursday, shares in Hampton, New Jerseyheadquartered Celldex Therapeutics Inc. recorded a trading volume of 3.36 million shares, whi...

Bicycle Therapeutics signs cancer development deal with CRUK

Cancer Research UK and its commercialisation arm are to work with UK biotech firm Bicycle Therapeutics on a novel approach to targeting cancer. Bicycle Therapeutics has developed a new class of thera...

Magenta Therapeutics Announces $48.5M Financing

NewsMagenta Therapeutics aspires to develop a patient-focused set of therapeutics with the first complete platform that addresses the critical challenges in stem cell transplant.

Biotech Stocks Under Scanner -- PTC Therapeutics, Arena Pharma, BioDelivery Sciences, and Seres ...

http://stock-callers.com/registration PTC Therapeutics  At the close on Tuesday, shares in South Plainfield, New Jerseyheadquartered PTC Therapeutics Inc. dropped 3.06%, ending the day at Read...

Heptares to buy G7 Therapeutics to expand GPCR capabilities

Sosei Group's subsidiary Heptares Therapeutics has agreed to acquire Swiss drugmaker G7 Therapeutics for CHF12m ($11.8m).

Multi-target collaboration across respiratory, cardiovascular and metabolic diseases for Bicycle Therapeutics

Bicycle Therapeutics, which is pioneering a new class of therapeutics based on its proprietary bicyclic…

Deals this week: Spero Therapeutics, BioCryst Pharmaceuticals, Breath Therapeutics Holding

Spero Therapeutics has announced it has raised $51.7m in a series C financing round led by GV (formerly Google Ventures).

Matching PubMed Articles

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement